Cloned antigens from Plasmodium falciparum as malaria vaccine candidates.
The problems of genetic polymorphism and poor immunogenicity of malaria vaccine candidates are discussed, with emphasis on the Circumsporozoite (CS) and p190 proteins of Plasmodium falciparum. It may be possible to use conserved regions of these proteins to raise protective immune responses against non-polymorphic determinants. Better adjuvants or delivery systems will be a critical factor in development of an effective vaccine.
Pink
J R
JR
Central Research Unit, F. Hoffmann-La Roche Ltd., Basle, Switzerland.
Caspers
P
P
Etlinger
H
H
Guttinger
M
M
Matile
H
H
Reber
R
R
Schönfeld
H J
HJ
Sinigaglia
F
F
Stüber
D
D
Stürchler
D
D
D000595:Amino Acid Sequence; D000818:Animals; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use; D003001:Cloning, Molecular / Q000379:methods; D006801:Humans; D008288:Malaria / Q000276:immunology*; D051379:Mice; D008815:Mice, Inbred Strains; D008969:Molecular Sequence Data; D010963:Plasmodium falciparum / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use; D013045:Species Specificity; D013601:T-Lymphocytes / Q000276:immunology; D014614:Vaccines, Synthetic
D000953:Antigens, Protozoan; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic